Guardant Health and AstraZeneca to develop companion diagnostics (CDx) and liquid biopsy tests

Posted by MarketsandMarkets on Dec 19, 2018 6:13:11 PM

On Dec 13, 2018 AstraZeneca, a global research based biopharmaceutical company, partnered with Guardant Health (US) for the development of CDx tests to commercialize AstraZeneca’s oncology portfolio including Tagrisso and Imfinzi. The CDx test is based on liquid biopsy platform supported by Guardant’s proprietary Digital Sequencing technology.

Read More

Topics: liquid biopsy, Medical Devices, healthcare, tumor mutational burden, blood-based companion diagnostics, cancer therapies

Recent Posts

Subscribe Here!

See all